ES2342083T3 - 3-piperidinilisocroman-5-oles como agonistas de dopamina. - Google Patents

3-piperidinilisocroman-5-oles como agonistas de dopamina. Download PDF

Info

Publication number
ES2342083T3
ES2342083T3 ES05740005T ES05740005T ES2342083T3 ES 2342083 T3 ES2342083 T3 ES 2342083T3 ES 05740005 T ES05740005 T ES 05740005T ES 05740005 T ES05740005 T ES 05740005T ES 2342083 T3 ES2342083 T3 ES 2342083T3
Authority
ES
Spain
Prior art keywords
methyl
piperidin
isochroman
aminomethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05740005T
Other languages
English (en)
Spanish (es)
Inventor
Gregory Shutske
Keith J. Harris
Kenneth J. Bordeau
Michael R. Angelastro
Stanly John
Joseph T. Klein
Jinqi Lu
Catherine Bomont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2342083T3 publication Critical patent/ES2342083T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES05740005T 2004-04-29 2005-04-27 3-piperidinilisocroman-5-oles como agonistas de dopamina. Expired - Lifetime ES2342083T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56655704P 2004-04-29 2004-04-29
US566557P 2004-04-29

Publications (1)

Publication Number Publication Date
ES2342083T3 true ES2342083T3 (es) 2010-07-01

Family

ID=34967397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05740005T Expired - Lifetime ES2342083T3 (es) 2004-04-29 2005-04-27 3-piperidinilisocroman-5-oles como agonistas de dopamina.

Country Status (11)

Country Link
US (1) US7919508B2 (enExample)
EP (1) EP1749001B1 (enExample)
JP (1) JP4685861B2 (enExample)
AR (1) AR050245A1 (enExample)
AT (1) ATE459618T1 (enExample)
DE (1) DE602005019719D1 (enExample)
DK (1) DK1749001T3 (enExample)
ES (1) ES2342083T3 (enExample)
PT (1) PT1749001E (enExample)
TW (1) TW200607802A (enExample)
WO (1) WO2005111025A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370104B (es) * 2013-10-22 2019-12-02 Chiesi Farm Spa Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).
CA2946990A1 (en) * 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
HRP20201469T1 (hr) * 2014-10-08 2020-12-11 UCB Biopharma SRL Derivati tetrahidroizokinolina
JP7187437B2 (ja) * 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
EP3490607A4 (en) * 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
JP7471818B2 (ja) 2016-08-18 2024-04-22 ヴィダック ファーマ リミテッド ピペラジン誘導体、医薬組成物、及びその使用方法
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN111196781B (zh) * 2018-11-16 2023-07-28 湖南中南制药有限责任公司 一种改进的制备五氟利多的方法
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
WO1998034933A1 (en) * 1997-02-07 1998-08-13 Hoechst Marion Roussel, Inc. (4-piperidinyl)-1h-2-benzopyran derivatives useful as antipsychotic agents
US6004982A (en) * 1997-09-15 1999-12-21 Hoechst Marion Roussel, Inc. 4-piperidinyl) H-2-benzopyran derivatives useful as antipsychotic agents

Also Published As

Publication number Publication date
DK1749001T3 (da) 2010-06-28
JP2007535548A (ja) 2007-12-06
US7919508B2 (en) 2011-04-05
JP4685861B2 (ja) 2011-05-18
PT1749001E (pt) 2010-05-31
AR050245A1 (es) 2006-10-11
WO2005111025A1 (en) 2005-11-24
DE602005019719D1 (de) 2010-04-15
TW200607802A (en) 2006-03-01
ATE459618T1 (de) 2010-03-15
EP1749001B1 (en) 2010-03-03
US20070099955A1 (en) 2007-05-03
EP1749001A1 (en) 2007-02-07

Similar Documents

Publication Publication Date Title
ES2550006T3 (es) Compuestos de amido y su uso como productos farmacéuticos
ES2286444T3 (es) Derivados de n-fenil(piperidin-2-il)metilbenzamida, su preparacion y su aplicacion en terapeutica.
ES2209462T3 (es) Agonistas de 5-ht1f.
US20080004312A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20060122197A1 (en) Amido compounds and their use as pharmaceuticals
US9765056B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
CA2635814A1 (en) Amido compounds and their use as pharmaceuticals
BRPI0308495B1 (pt) Composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto
ES2585244T3 (es) Composiciones y métodos para modular una cinasa
HRP20010468A2 (en) Azabicycloalkanes as ccr5 modulators
SK15852000A3 (sk) Derivát 1-[(1-substituovaného-4-piperidinyl)metyl]-4-piperidínu, spôsob jeho prípravy, farmaceutický prípravok obsahujúci tento derivát a medziprodukt tohto derivátu
JPWO2009022731A1 (ja) P2x4受容体拮抗剤
ES2342083T3 (es) 3-piperidinilisocroman-5-oles como agonistas de dopamina.
JP5727011B2 (ja) ブラジキニンb1受容体のアンタゴニストとしての二置換テトラヒドロフラニル化合物
US8722896B2 (en) Prokineticin receptor antagonists and uses thereof
JP2014506905A (ja) 新規なベンゾジオキソールピペリジン化合物
KR101523776B1 (ko) 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
US8268853B2 (en) 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
ES2252471T3 (es) Nuevos derivados de heteroarilo, su preparacion y uso.
ES2220582T3 (es) Derivados de piperidina y su uso como antagonistas de receptor de serotonina.
ES2321217T3 (es) Inhibidores del transporte de glicina.
JP5727010B2 (ja) ブラジキニンb1受容体のアンタゴニストとしてのピリダジン誘導体
ES2259619T3 (es) Derivados de indol para el tratamiento de depresion y ansiedad.
ES2345261T3 (es) Derivados de 4-amino-piperidina como inhibidores de la captacion de monoamina.
CN117105872B (zh) 苯并二氮杂䓬类化合物及其制备方法与用途